Radius Health Inc (RDUS) Major Shareholder Purchases $2,578,500.00 in Stock

Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech bought 75,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were purchased at an average cost of $34.38 per share, for a total transaction of $2,578,500.00. Following the completion of the acquisition, the insider now owns 5,773,799 shares of the company’s stock, valued at $198,503,209.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Radius Health Inc (NASDAQ RDUS) opened at $38.63 on Thursday. The firm has a market capitalization of $1,720.00, a PE ratio of -7.11 and a beta of 1.21. Radius Health Inc has a 12 month low of $24.66 and a 12 month high of $49.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.

A number of research analysts recently issued reports on RDUS shares. Jefferies Group lowered their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 target price on shares of Radius Health in a report on Friday, November 3rd. ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Citigroup started coverage on Radius Health in a report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 target price on the stock. Finally, BidaskClub lowered Radius Health from a “sell” rating to a “strong sell” rating in a report on Thursday, December 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $51.78.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its stake in Radius Health by 19.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in Radius Health by 4.1% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 690 shares in the last quarter. Principal Financial Group Inc. increased its stake in Radius Health by 14.1% in the 2nd quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after purchasing an additional 839 shares in the last quarter. California Public Employees Retirement System increased its stake in Radius Health by 2.3% in the 2nd quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock worth $3,238,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in Radius Health by 0.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 182,575 shares of the biopharmaceutical company’s stock worth $5,801,000 after purchasing an additional 1,674 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This news story was first published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://weekherald.com/2018/02/15/radius-health-inc-rdus-major-shareholder-purchases-2578500-00-in-stock.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply